tiprankstipranks
Trending News
More News >

Rachel King Insider Profile

11 Followers
Rachel King, Director at Crescent Biopharma, holds 25.19K shares in Novavax (Ticker: NVAX), holds 659.10K shares in Crescent Biopharma (Ticker: CBIO), holds ― shares in Fulcrum Therapeutics (Ticker: FULC).
tipranks
Rachel King

Rachel King
Crescent Biopharma (CBIO)
Director

Ranked #72,313 out of 102,830 Corporate Insiders

Profitable Transactions

40%
2 out of 5 Profitable Transactions

Average Return

-12.30%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$8M
97.95%
2.05%
0.00%
A breakdown of Rachel King's holdings

Insider Roles

Crescent Biopharma
(CBIO)
Director
Novavax
(NVAX)
Director
Fulcrum Therapeutics
(FULC)
Director
Roles that Rachel King holds in companies

Most Profitable Insider Trade

Stock:
Novavax
(NVAX)
Rating:Informative Sell
Date:Jan 02, 2025 - Today
Return:+23.40%
The most profitable trade made by Rachel King

Rachel King's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
Crescent Biopharma
Apr 02, 2024
Director
Uninformative Buy
10.00K
$7.91M
Novavax
Jun 13, 2025
Director
Uninformative Buy
74.50K
$165.25K
Fulcrum Therapeutics
Director
List of latest transactions for each holding click on a transaction to see Rachel King's performance on stock

Rachel King insider profile FAQ

What is the percentage of profitable transactions made by Rachel King?
The percentage of profitable transactions made by Rachel King is 40%.
    What is the average return per transaction made by Rachel King?
    The average return per transaction made by Rachel King is -12.30%.
      What stocks does Rachel King hold?
      Rachel King holds: CBIO, NVAX, FULC stocks.
        What was Rachel King’s latest transaction?
        Rachel King latest transaction was an Uninformative Buy of $74.50K.
          What was Rachel King's most profitable transaction?
          Rachel King’s most profitable transaction was an Informative Sell of NVAX stock on January 2, 2025. The return on the trade was 23.40%.
            What is Rachel King's role in Crescent Biopharma?
            Rachel King's role in Crescent Biopharma is Director.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.